I'm hardly knowledgeable in FDA approvals mate but I'd have thought if MSB is successful, that the FDA will have basically ticked off on the safety and manufacturing side for future applications concerning Remestemcel-L. So in that regard it would be easier, I'd think. It will certainly be a game changer for medicine though.
I have everything crossed.
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-699
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.105(8.43%) |
Mkt cap ! $1.541B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $16.46M | 12.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 59739 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |